Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  BB BIOTECH AG    BION   CH0038389992

BB BIOTECH AG (BION)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
01/11/2018 01/12/2018 01/15/2018 01/16/2018 01/17/2018 Date
68.5(c) 69.3(c) 68.4(c) 68.8(c) 68.4(c) Last
72 784 93 593 93 028 59 831 86 043 Volume
+0.59% +1.17% -1.30% +0.58% -0.58% Change
More quotes
Financials ( CHF)
Sales 2017 -
EBIT 2017 729 M
Net income 2017 654 M
Debt 2017 262 M
Yield 2017 4,32%
Sales 2018 -
EBIT 2018 570 M
Net income 2018 570 M
Debt 2018 309 M
Yield 2018 4,43%
P/E ratio 2017 6,09
P/E ratio 2018 6,63
EV / Sales2017 0
EV / Sales2018 0
Capitalization 3 812 M
More Financials
Company
BB Biotech AG is a closed-end investment fund, which engages in the investments in the biotechnology companies.It focuses on listed companies that are developing and commercializing novel medical treatments and cures.The company was founded on November 9, 1993 and is headquartered in Schaffhausen,... 
Sector
Biotechnology & Medical Research
Calendar
02/16 | 01:00amEarnings Release
More about the company
Surperformance© ratings of BB BIOTECH AG
Trading Rating : - Investor Rating :
More Ratings
Latest news on BB BIOTECH AG
2017 BB BIOTECH : statement on MiFID II
2017 BB BIOTECH AG : Product approvals and solid company results lead the biotech sec..
2017 DGAP-ADHOC : BB BIOTECH AG: Tailwind for biotech investors
2017 BB BIOTECH AG : Novel drugs to battle cancer on the verge of market launch
2017 DGAP-DD : BB BIOTECH AG english
2017 DGAP-DD : BB BIOTECH AG deutsch
2017 DGAP-DD : BB BIOTECH AG english
2017 DGAP-ADHOC : BB Biotech meldet erfreuliches Quartalsergebnis
2017 DGAP-ADHOC : BB Biotech reports pleasing quarterly results
2017 DGAP-ADHOC : BB Biotech archivia il primo trimestre con risultati incoraggianti
More news
Sector news : Biotechnology & Medical Research - NEC
02:48a CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
01/10BRIEF-BB Biotech Reports 5.6% Passive Stake In Voyager Therapeutics  
01/03The Medicines Company to Present at the 36th Annual J. P. Morgan Healthcare C.. 
2017Clive Meanwell Sells 136,250 Shares of The Medicines Company $MDCO Stock  
2017BB Biotech statement on MiFID II (news with additional features)  
2017BB BIOTECH AG: Product approvals and solid company results lead the biotech s.. 
More tweets
Qtime:41
News from SeekingAlpha
2016 Myovant Sciences IPO Attracts Major Pharma Interest
2015 WINNERS CIRCLE 2014 TOP HEDGE FUND M : Healthcare Funds, Nine Of Top Ten Spots
Chart BB BIOTECH AG
Duration : Period :
BB BIOTECH AG Technical Analysis Chart | BION | CH0038389992 | 4-Traders
Technical analysis trends BB BIOTECH AG
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 69,4  CHF
Spread / Average Target 0,93%
EPS Revisions
Managers
NameTitle
Erich Hunziker Chairman
Clive A. Meanwell Vice Chairman
Klaus Strein Director
Claude Mikkelsen Director-Investor Relations
Felicia Flanigan Senior Biotech Analyst
Sector and Competitors
1st jan.Capitalization (M$)
BB BIOTECH AG6.58%3 959
CELLTRION, INC.--.--%41 248
IQVIA HOLDINGS INC2.19%20 807
LONZA GROUP0.42%20 432
INCYTE CORPORATION-0.68%19 852
ALNYLAM PHARMACEUTICALS, INC.1.59%12 692